CA-NETAPP
NetApp ® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced continued innovations and solutions to provide enterprises with more simplicity, more security and more flexibility for their hybrid multicloud environments.
These new capabilities include improved ransomware protection, hybrid cloud storage in a single subscription, unified management in a single user interface, and close collaboration with VMware to help transition workloads to the cloud.
As enterprises acquire public cloud services to augment their existing on-premises data centers, these combined infrastructures become more disparate, inconsistent and fragmented over time. These multicloud silos are inherently more complex to manage due to dealing with multiple disparate environments.
Today, NetApp is delivering a unified and consistent hybrid multicloud experience, allowing customers to run and manage a single platform that spans from on-premises to the world’s biggest public clouds.
“As organizations today explore the promise of hybrid multicloud environments, they are keen to avoid complexity, security, and cost efficiency challenges,” said Ronen Schwartz, senior vice president, Cloud Volumes Service at NetApp. “With NetApp’s simplified management and consumption experience, organizations can enjoy improved security, manageability, speed of operations, and cost savings - ultimately allowing them to be more responsive to the growing needs of their business by delivering capabilities faster, and keeping data available and protected no matter where it lives.”
Simple, secure, and flexible enhancements to NetApp’s hybrid cloud portfolio include:
Industry-Leading Hybrid Cloud Simplicity Experience –
By delivering everything "as a service," NetApp simplifies and optimizes hybrid cloud environments with new capabilities, including:
- Hybrid cloud Storage-as-a-Service (STaaS) in a single, flexible subscription with Keystone. Organizations can flexibly move workloads to and from the cloud in a single contract.
- In addition to managing and monitoring data storage, protection, governance and tiering across multicloud environments, Cloud Manager can now manage Keystone services, track software licenses, monitor infrastructure health and provide proactive recommendations that optimize costs and data protection with automated actions.
"Organizations today are looking for flexibility both on-premises as well as across cloud providers and are investing in as-a-service consumption models to help achieve this," said Scott Sinclair, practice director at ESG. "NetApp's approach with Keystone is targeted at that need; offering hybrid cloud simplicity and flexibility that allows users to accelerate their IT objectives with management, orchestration, and billing wrapped into a single subscription and experience. Keystone's transferable subscription model also supports future cloud migration planning to any major cloud provider, with enterprise-level storage capability and integrated data protection."
Cyber Resilience for Today’s Hybrid Cloud –
The rise of ransomware over the past few years is a growing problem for enterprises. IDC’s 2021 Ransomware Study: Where You Are Matters! 1 found that more than one third of organizations worldwide have experienced a ransomware attack or breach that blocked access to systems or data in the 12 months prior.
With NetApp’s new, powerful, built-in cyber resilience capabilities that include anti-ransomware, data protection and security - organizations can mitigate unauthorized user access and threats to data from ransomware attacks. Customers can protect a multitude of workloads, enterprise apps, virtualized workloads and modern containerized applications against security breaches, quickly detect attacks and rapidly recover data before experiencing any impact to operations.
Accelerating Enterprise Cloud Transformation –
NetApp is empowering customers to “modernize to the cloud” using a supplemental datastore for data-intensive, storage demanding workloads running in a single or across multicloud environments. NetApp is the only cloud storage service provider today to be certified and become supported for use as an external supplemental datastore for VMware Cloud environments running in the largest public clouds.
“Organizations across all industries rely on the combination of VMware and NetApp as the platform of choice for delivering business-critical workloads,” said Narayan Bharadwaj, vice president of Cloud Solutions at VMware. “NetApp is now able to deliver the same levels of enterprise-class data management that our mutual customers have enjoyed for decades on-premises to workloads running in any of the major public clouds.”
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
1 IDC's 2021 Ransomware Study: Where You Are Matters! (IDC #US US48093721) July 2021
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom